CPC A61K 9/1271 (2013.01) [A61K 9/127 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 45/06 (2013.01); A61K 47/34 (2013.01); A61P 29/00 (2018.01); A61P 31/06 (2018.01); A61P 37/08 (2018.01)] | 20 Claims |
1. A method for treating inflammation associated with an allergy or a disease in a subject in need thereof, the method comprising administering, orally or sublingually, (1) a first active agent encapsulated in a first liposome carrier that comprises: i) poly (ethylene glycol) distearoylphosphatidylethanolamine (PEG-DSPE), ii) phosphatidylglycerol, phosphatidylcholine, or a combination thereof, and iii) a pH sensitive component which causes the liposome to release the first active agent in a pH range of about pH 1 to about pH 5; and (2) a second active agent encapsulated in a second liposome carrier that comprises: i) poly (ethylene glycol) distearoylphosphatidylethanolamine (PEG-DSPE), ii) phosphatidylglycerol, phosphatidylcholine, or a combination thereof, wherein the second liposome carrier releases the second active agent in a pH range of about pH 6 to about pH 8.
|